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Abstract: 
Sustained release of drug delivery systems (DDS) has the capacity to increase cancer 
treatment efficiency in terms of drug dosage reduction and subsequent decrease of 
deleterious side effects. In this regard, many biomaterials are being investigated but none 
offers morphometric and functional plasticity and versatility comparable to protein-based 
nanoparticles (pNPs). Here we describe a new DDS by which pNPs fabricated as bacterial 
inclusion bodies (IB) can be easily isolated, subcutaneously injected and used as 
reservoirs for the sustained release of targeted pNPs. Our approach combines the high 
performance of pNP, regarding specific cell targeting and biodistribution with the IB 
supramolecular organization, stability and cost effectiveness. This renders a platform able 
to provide a sustained source of CXCR4-targeted pNPs that selectively accumulate in 
tumor cells in a CXCR4+ colorectal cancer xenograft model. In addition, the proposed 
system could be potentially adapted to any other protein construct offering a plethora of 
possible new therapeutic applications in nanomedicine.  
  
Introduction: 
Metastatic dissemination in cancer is a consequence of the highly invasive disease and 
cannot be solely treated by surgery and radiation. In this regard, co-adjuvant 
chemotherapy using genotoxic drugs is regularly administered to patients as main 
systemic therapy [1]. Genotoxic drugs are capable of efficiently inducing cancer cell death 
but they also affect other fast growing healthy cells such as gastrointestinal tract and bone 
marrow cells due to their lack of targeting. This renders important deleterious side effects 
and the subsequent dose limitations. In addition, chemotherapy has failed in the treatment 
of advanced stages of the disease and tumor resistance is often observed during relapses 
[2,3]. The appearance of nanotechnological approaches coupled with the increasing 
understanding of disease biology, have prompted an important push on the development 
of more efficient pharmacological strategies [4].Thus, the available knowledge concerning 
specific cancer cell receptors and signaling pathways intermediates that are involved in 
disease progression and spread, provides promising tools to attack the disease in new and 
more efficient ways [5]. 
Nanoparticles (NPs) have shown potential to reduce systemic toxicity, by the entrapment 
of the chemotherapeutic agent as well as by reducing needed drug dosage, due to their 
ability to accumulate into the tumor through the enhanced permeability and retention effect 
(EPR [6]). Moreover, the use of nano sized drug delivery systems (DDS) allows the 
incorporation of targeting ligands to direct these nanoparticles to specific tissues or cells 
that often increase uptake efficiency, reduce off-target effects and therefore improve their 
therapeutic benefit [7]. Among the milieu of ongoing biomaterials for DDS fabrication, 
protein based approaches result highly appealing. In particular, self-assembled protein 
nanoparticles (pNPs) can represent suitable nanosized carriers due to their high 
biocompatibility and functional plasticity. Their protein nature permits to incorporate, by 
regular genetic engineering, uncountable combinations of motifs and domains that 
respond to specific pharmacological needs. In this regard, recent studies have shown the 
generation of self-assembling protein NPs (pNPs) able to target CXCR4 [8], CD44 [9], 
LDLR [10] and EGFR [11] among others. In these cases the ligands T22 (CXCR4), R9 
(CXCR4), A5 (CD44) and Seq-1 (LDLR) were combined with a GFP scaffold for 
traceability while specific Anti-EGFR repebody fused to the cytolytic domain Apoptin was 
employed as a proof of concept for pNPs with therapeutic activity. Particularly interesting 
for our study are the T22 and R9 peptides. These ligands, with a high specificity for 
CXCR4 receptor [12,13,14], overexpressed in metastatic colorectal cancer [15,16], have 
been successfully employed to direct and increase pNP cell penetration in CXCR4 positive 
tumor cells. Also, T22 and R9 are efficient architectonic tags that upon incorporation in the 
amino terminal of the protein and in combination with a carboxy terminal poly-His tag, 
induce the self-assembling of GFP into regular sized nanoparticles [17]. In this context, 
T22-empowered protein nanoparticles (T22-GFP-H6) have shown selective biodistribution 
and accumulation into the primary tumor as well as in all the macro and micro metastatic 
foci upon intravenous (i.v.) administration in an orthotopic colorectal cancer mouse model 
in absence of any off-target accumulation and toxicity [18]. However, short term stability 
within the body and fast pNP clearance from bloodstream are pivotal barriers to surpass in 
order to achieve reliable therapeutic alternatives. These drawbacks imply periodical 
administration of the pNPs and the exposition of the patient to peaks of highly 
concentrated genotoxic drugs what increases stress associated to treatment. In this 
regard, immobilized drug delivery platforms capable of a sustained release pose an 
interesting alternative to intravenous administered drugs since they maintain a constant 
and long lasting drug concentration in the bloodstream. 
Bacterial Inclusion Bodies (IBs) are amyloid like protein particles that occur during 
recombinant biofabrication processes. These particles gather many features from pNPs, 
like their capability to be modified in the genetic source, following a bottom up approach, in 
order to obtain functionally diverse carriers [19,20]. Nevertheless, IBs are significantly 
bigger entities than pNPs, with diameters from 100 nm up to 1 µm, belonging to the 
insoluble fraction under physiological conditions, what makes them easier to isolate in a 
cost effective manner. IBs are structured in a sponge like conformation in which a network 
of amyloid fibrils holds quasi soluble protein species [21]. These structures have been 
shown to act as other functional amyloids like the secretory granules found in the 
endocrine system [22]. IBs contain functional protein that can be released along time 
under the appropriate conditions [23].These features have been previously described and 
exploited rendering promising results in terms of protein stability and biocompatibility in 
both, in vitro and in vivo approaches, when a given protein is administered packed as IBs 
[24,25,26].  Nevertheless, nanostructured protein release from IBs has never been 
described.  
In this work, we report for the first time the use of IBs as reservoirs of targeted pNPs. We 
describe direct release of self-assembled pNPs from IBs in a fully functional way in vitro 
and in vivo. In this regard, it is important to highlight that released pNPs are able to 
effectively target cells and tissues by specific receptor recognition. Our system exploits the 
combined nanoscale properties provided by pNPs with the mesoscale features of the IBs. 
In addition, we show the potential of implantable IBs to provide a long lasting source of 
targeted pNPs actively directed to distant sites from the primary implantation point.   
In detail, two modular self-assembling proteins targeting CXCR4 receptor, T22-GFP-H6 
and R9-GFP-H6, were produced as IBs. These IBs released pNPs specifically directed to 
CXCR4+ cells in both, in vitro and in vivo models. Importantly, T22-GFP-H6 IBs provided 
significant amounts of targeted pNPs as long as 10 days after subcutaneous implantation 
in a xenograft colorectal cancer mouse model that traveled through the bloodstream to 
efficiently accumulate in target CXCR4+ tumor cells.  
 
Materials and Methods: 
Protein overexpression and Inclusion body isolation. 
T22-GFP-H6, R9-GFP-H6 and VP1-GFP (Gene bank accession number: KM242650.1) 
modular proteins were coded by the expression vectors pET22b (Novagen), pET21a 
(Novagen) and pTrc99a respectively. T22 and R9 are cationic peptide ligands to the 
CXCR4 receptor while VP1 is a foot and mouth disease virus capsid protein employed as 
aggregation domain to favor IB deposition. These domains were fused to a green 
fluorescent protein (GFP). In the cases of R9-GFP-H6 and T22-GFP-H6 a polyhistidine tag 
was also incorporated to the c-terminus of the modular protein as an architectonic tag to 
induce the self-assembling of the resulting modular proteins in combination with the 
cationic n-terminal peptide. The constructs encoding T22-GFP-H6, R9-GFP-H6  and VP1-
GFP were transformed into the Escherichia coli (E. coli) strains Origami B, Rosetta (DE3) 
and  JGT4 [27] respectively. 
IB production was carried out in 400 mL of Luria Broth (LB) in 2 L shake flasks by 
conventional protein over expression. Briefly, induction of protein production was 
performed by 1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) addition (final 
concentration) in bacterial cell cultures at early exponential growth phase, OD550 at 0.5. 
Bacterial cell cultures were further incubated for 3 h at 37 °C and 250 rpm. Samples were 
then harvested by centrifugation, 10.000 g for 15 min at 4 °C and a combination of 
mechanical and enzymatic procedures was applied for cell disruption. First, cell pellets 
were resuspended in lysis buffer (50 mM Tris- HCl, 10 mM NaCl, 1 mM EDTA) and 
protease inhibitors: phenylmethylsulfonyl (PMSF) 0.4 mM and Complete EDTA-Free 
(Roche) added. Then, enzymatic digestion was carried out by lysozyme added at 1µg/mL 
for 2h at 37 ºC and 250 rpm. After cell wall digestion, five rounds of French Press at 1200 
psi were carried out and lysates were frozen at -80 °C. Samples were thawed and mild 
detergent washing was performed by Triton X-100 addition (0.2 % v/v) for 1h at room 
temperature (RT) under vigorous agitation. IBs were collected by centrifugation at 15.000 
g for 15 min at 4 ºC and resuspended again in lysis buffer to wash out previous purification 
reagents. DNAse treatment, 0.6 µg/mL 1 h at 37 ºC, was performed and presence of 
remaining viable bacteria checked by plating 100 µL of IBs sample onto LB plates and 
culturing them overnight (ON) at 37 ºC. Freeze/Thaw cycles were applied until no colony 
was observed on the plates. Finally, IBs were washed in deionized sterile water, 
centrifuged at 15.000 g for 15 min at 4 ºC, and pellets stored at -80 °C until further use. IB 
quantification was carried out by western blot against GFP protein using GFP-H6 soluble 
protein at known concentration to generate the standard curve from which IBs 
quantification was inferred. This quantification was performed by ImageJ software (NIH). 
13.35 µg of T22-GFP-H6, 3.15 µg of R9-GFP-H6 and 3.55 µg of VP1-GFP IBs per mL of 
cell culture were obtained respectively. 
IB visualization in the producing bacteria strain 
After IB production, cells were centrifuged at 5000 g for 15 min and the pellet was 
resuspended and fixed using a 4 % paraformaldehyde solution for 30 min at room 
temperature (RT). Samples were then observed under a Leica TCS-SP5 confocal laser 
scanning microscope (Leica Microsystems CMS GmbH) in a Plan-Apochromatic 63x (NA 
1.4, oil) objective. GFP-based proteins were excited with an Argon laser (488 nm). Finally, 
an intensity colored palette was applied to the obtained images using ImageJ software in 
order to improve fluorescence distribution observation.  
Protein release in vitro 
Purified IBs were resuspended in phosphate buffered saline (PBS) at 1 mg/mL, and 
incubated at 37 °C. Samples were taken at 0 h, 0.5 h, 1 h, 3 h, and 24 h and centrifuged 
for 15 min at 15000 g and 4 °C. Soluble and insoluble fractions were further processed for 
western blot and FESEM imaging. In all the cases pellets corresponding to the insoluble 
fraction (IBs) were resuspended in PBS at the same final volume than their soluble 
counterpart (pNPs) for comparison.  
Field Emission Scanning Electron Microscopy (FESEM) 
Microdrops of 3 μL of triplicate samples were directly deposited onto silicon wafers (Ted 
Pella Inc.) for 2 min and sample excess removed by capillarity using filter Whatman paper 
(GE Healthcare). Samples were further air dried and immediately observed at nearly 
native state without coating with a high resolution in-lens secondary electron detector in a 
Zeiss Merlin FESEM operating at 2 kV. For the qualitative approach, representative 
images of either insoluble (IBs, 200,000x of magnification) and soluble fractions (pNPs, 
350,000x of magnification) coming from protein release in vitro assay were obtained. For 
the quantitative approach, representative images at 170,000x magnification of pNPs 
isolated at the optimal release incubation points observed by western blot (0.5 h and 3 h, 
respectively) were obtained. The diameter of randomly distributed 1795 particles from R9-
GFP-H6 supernatants and 3637 from T22-GFP-H6 supernatants was determined for the 
size distribution assessment using ImageJ software (NIH). 
Western blotting  
Regular western blotting procedures were employed to analyze soluble and insoluble 
fraction from IBs. Briefly, equal volumes of each fraction were diluted in laemmli 4x loading 
buffer. Insoluble and soluble fractions were boiled for 25 min and 5 min respectively at 98 
°C and then 20 µL loaded into a 15 % sodium dodecyl sulfate (SDS) polyacrylamide 
electrophoresis gel. Gel running was carried out at a constant voltage of 100 V and 
transferred to a nitrocellulose membrane. GFP domain from the three model proteins 
employed in the study was detected using a rabbit polyclonal anti-GFP antibody (Santa 
Cruz Biotechnology) followed by a goat anti-rabbit secondary antibody conjugated to a 
horseradish peroxidase (BioRad). Membrane was developed by the addition of 
chloronaphthol and hydrogen peroxide. Densitometric analysis of the protein bands 
allowed us to determine relative amounts of protein between soluble and insoluble fraction. 
All the blots were performed in triplicate from independent experiments. 
Cell culture and pNP uptake assays 
HeLa cells acquired at ATCC (CCL2) were routinely cultured in MEM alpha medium 
(Gibco) containing 10% of fetal bovine serum (Gibco) in a humidified incubator a 37 °C 
and 5 % CO2. Note that the material used in the uptake experiments correspond to pNPs 
released from IBs and come from the soluble fraction of IBs suspension isolated by high 
speed centrifugation (15.000 g, 15 min, 4°C). 
Flow cytometry 
Particle uptake assays were performed in 24 well plates at 70% of cell confluence. 2.5 µL 
samples from soluble fractions (pNPs), coming from 1 mg/mL IB suspension, were added 
per well and incubated for 1 h at cell culture conditions. Then, incubation plates were 
washed in DPBS (Gibco) and treated with trypsin at 1 mg/mL (Gibco) for 15 min at 37 °C. 
This “harsh” trypsin digestion allowed to completely remove protein externally adhered to 
cells [28].Competition assays were performed as described above following incubation 
with 1 µM of AMD3100 (Sigma) for 1 h at 37 °C and 5 % CO2. Note that AMD3100 
(octahydrochloride hydrate) has been described as a potent CXCR4 receptor antagonist. 
Cells were then processed in a FACS-Canto flow cytometer (Becton Dickinson) using a 15 
mW air-cooled argon ion laser at 488 nm for GFP fluorescence excitation and a D detector 
(530/30 nm bandpass filter) for detection of their fluorescence emission.  
Confocal Microscopy 
Nanoparticle uptake was also assessed by confocal microscopy. HeLa cells were cultured 
in MatTek culture dishes (MatTek Corp.) until reaching subconfluency. The soluble 
fractions, containing pNP released from 1 mg/mL IBs suspension, were added and further 
incubated during 1 h. Cell membranes were stained with CellMaskTM DeepRed 
(Molecular Probes) and nuclei with Hoescht 33342 (Molecular Probes) for 10 min before 
being washed in PBS. Cells were then recorded with a Leica TCS-SP5 confocal laser 
scanning microscope (Leica Microsystems CMS GmbH) using an Apo63x/1.4 (oil HC x PL 
APO lambda blue) objective. GFP-based pNPs were excited by an Argon laser (488 nm), 
Cell mask by a HeNe laser (633nm) and Hoescht by a blue diode (405 nm). 
In vivo biodistribution of bacterial IBs 
Five-week-old female Swiss nu/nu mice weighing between 18 and 20 g (Charles River) 
and maintained in SPF conditions, were used for in vivo studies. All the in vivo procedures 
were approved by the Hospital de Sant Pau Animal Ethics Committee and performed 
according to European Council directives. To generate the subcutaneous (SC) mouse 
model, 10 mg of SP5 CCR tumor tissue were obtained from donor animals, and 
subcutaneously implanted in the anterior flanks of experimental Swiss nu/nu mice. When 
tumors reached 500 mm3 approximately, mice were randomly allocated and 
subcutaneously administered in the mouse posterior flank, far away from the tumor, with 
T22-GFP-H6 or VP1-GFP bacterial IBs at 1 mg/mouse dose resuspended in a 150 µL 
saline solution. Control mice were administered with the same volume of saline solution.  
After IBs administration, whole- body mice were monitored at short (5 h) and long-times (1 
d, 2 d, 5 d and 10 d) to determine the retained GFP fluorescence in the subcutaneous IB 
implants located in the posterior mouse flank using the IVIS® Spectrum equipment 
(PerkinElmer Inc.). Following, 1 mL of blood was collected by intracardiac puncture and 
plasma was obtained by centrifuging at 600g, 10min, 4 ºC.  Fluorescence emitted by the 
obtained plasma was, then, recorded ex-vivo using the IVIS equipment at the selected 
times (5 h, 1 d, 2 d, 5 d and 10 d) post-administration of bacterial IBs. Mice were 
subsequently euthanized and tumor, brain, lung and heart, kidney, liver and bone marrow 
were collected and examined separately for ex-vivo GFP fluorescence in an IVIS® 
Spectrum equipment.  
 The fluorescent signal (FLI) was first digitalized, displayed as a pseudocolor overlay, and 
expressed as radiant efficiency. The FLI ratio was calculated dividing the FLI signal from 
the protein-treated mice by the FLI auto-fluorescent signal of control mice. In order to 
estimate the percent of the subcutaneously injected IBs dose that reached the tumor or 
normal organs, we calculated the Area Under the Curve (AUC (mg x day)). This was done 
after plotting the amount of protein (mg) versus time (days) for each localization, and 
applying the trapezoidal method, considering the following equivalencies at time 0 min 
after SC administration. 5.57 x 109 and 1.24 x 1010 fluorescent units were equivalent to 1 
mg of T22-GFP-H6 IBs protein or 1 mg of VP1-GFP IBs protein, respectively 
 Multiple immunofluorescence assay. 
The presence and localization of IBs and released pNPs around the injection point in the 
mouse posterior flank (as subcutaneous depositions), into blood vessels of the hypodermis 
and in tumor tissue of the anterior mouse flank were assessed by multiple 
immunofluorescence labeling of formalin-fixed paraffin-embedded (FFPE) samples using 
standard protocols. Samples were taken after 5 d upon IBs administration. Primary 
antibodies anti-GFP (1:250, Abcam) and anti-PECAM-1 (1:200; Santa Cruz Biotechnology, 
Inc.) were incubated ON at 4 ºC. Then, the secondary antibodies: donkey anti-goat IgG-
Cy3 (Jackson) for PECAM-1 and chicken IgG-Cy2 for GFP. Slides were then stained with 
DAPI (1:10000 in TBS) for 10 min RT, rinsed with water, mounted and analyzed under 
fluorescence microscope (405 nm, 488 Cy2 and 532/561 filters). Representative pictures 
were taken using confocal Leica TCS SPE at 400x magnification. 
Statistical analysis 
T- tests assuming unequal variances were performed to assess differences in in vitro 
assays with a minimum n=3. Past3 open access software was employed to carry out 
statistical analysis. The Mann–Whitney U-tests were used to compare tumor tissue 
fluorescence emission (FLI) between groups in in vivo experiment, using the SPSS vs11.0 
package (IBM). All quantitative values were expressed as mean ± standard error of the 
mean (SEM).. Differences between groups were considered significant at p < 0.05.  
Results: 
Bacterial IBs formed by the recombinant modular proteins VP1-GFP, R9-GFP-H6 and 
T22-GFP-H6, detailed in Figure 1, panel a, were successfully produced in E. coli cell 
factories. Protein overexpression rendered insoluble protein deposits in the range from 
100 nm to 800 nm in diameter. IB size characterization of the material used in the present 
work was performed in a previous study [20]. As it can be observed in Figure 1b, left 
panel, focused fluorescent signal showed IB deposition at the bacteria poles but we also 
detected fluorescence all over the cytoplasm indicating presence of their soluble 
counterpart. In addition, the co-existence of soluble and insoluble protein species within 
the bacteria exhibited distinct patterns depending on the IB fabrication setup, namely 
producing strain and IB forming protein. In this regard T22-GFP-H6 and R9-GFP-H6 
producing bacteria showed a higher extent of soluble protein than VP1-GFP samples.  
FESEM micrographs of purified IBs revealed pseudo-spherical particles with different 
grades of surface complexity. VP1-GFP IBs displayed mostly smooth surface while R9-
GFP-H6 and T22-GFP-H6 IBs showed increased surface roughness exhibiting a 
particulate coating. Interestingly, significantly smaller particles were also observed nearby 
R9-GFP-H6 and T22-GFP-H6 IBs suggesting a direct release of pNPs from IBs (Figure 
1b, right panel). In order to study in detail this event we further analyzed by FESEM the 
soluble fractions obtained after the centrifugation of purified IBs suspensions where we 
efficiently separate IBs form released soluble protein material. In these soluble samples, 
we observed rounded nanostructures confirming pNPs release from the main aggregate 
(IBs) (Figure 1c). Of note R9-GFP-H6 and T22-GFP-H6 have been previously described 
as proteins with self-assembling capacity able to effectively generate soluble pNP driven 
by the presence of positively charged peptides at the amino terminus such as T22 and R9 
in combination with a polyhistidine tag at the carboxy terminus (Figure 1, panel a) [17]. 
Qualitative evaluation of pNPs depicted in FESEM images revealed a rather polydisperse 
size distribution exposing particles with diameters sizing from 20 nm to 80 nm in both T22-
GFP-H6 and R9-GFP-H6 samples. Additionally, magnification of pNPs showed a brighter 
outer ring and darker inner region within nanoparticle architecture. This observation 
suggested a toroidal conformation of the pNPs in accordance with previous studies [29]. 
As expected, VP1-GFP samples did not show any nanostructured entity in its soluble 
fraction since the fusion protein lacks the oligomerization domains. 
  
Figure 1.  Architectonic features of T22-GFP-H6, R9-GFP-H6 and VP1GFP a) Schematic 
representation of the aggregation model protein VP1-GFP and the self-assembling modular 
proteins R9-GFP-H6 and T22-GFP-H6. Sizes of the boxes are only indicative b) Left panel, confocal 
images of bacteria producing IBs. Right panel, FESEM micrographs of isolated IBs. c) FESEM 
detail of pNPs (present in the soluble fraction) isolated from purified IBs (insoluble fraction). pNPs 
were obtained by isolating by centrifugation the soluble fraction of an IB suspension at 1 mg/ mL .   
Next we studied protein release from IBs (insoluble fraction) to the soluble fraction at 
different time points (Figure 2a). For this, IBs were resuspended in PBS at 1 mg/mL and 
incubated at 37 ºC.  Soluble and insoluble fractions were then isolated from these samples 
at different times and presence of protein immune detected by western blot. Protein 
amount released from IBs to the soluble fraction was higher for T22-GFP-H6 samples than 
for R9-GFP-H6 at longer incubation times. VP1-GFP did not show detectable amounts of 
protein in the soluble fraction at any tested time. Interestingly, T22-GFP-H6 exhibited 
increasing amounts of protein in the soluble fraction reaching its maximum at 3 h in which 
the soluble protein corresponded to the 14.6 % of the total protein, but rendering clearly 
detectable bands till 24 h after IBs resuspension (10 % of soluble protein). This profile was 
indicative of a progressive protein release from IBs. In the case of R9-GFP-H6 samples, 
the amount of protein obtained in the soluble fraction could be detected till 3 h after 
incubation with a maximum intensity at 30 min, 16 % of soluble protein. Interestingly, at 
longer incubations time points the amount of released protein exhibited a marked drop. 
R9-GFP-H6 IBs may contain an external layer of loosed pNPs easily resolubilized but with 
a poor stability in the assay conditions (Figure 2a and ai). In order to analyze in vitro if the 
released protein from IBs occurred in form of single polypeptides or arranged as self-
assembled pNPs, a morphometric analysis of ultrastructure was performed for the soluble 
fraction of IBs suspensions at distinct incubation times with FESEM (Figure 2b). Abundant 
pNPs were observed in accordance with previous results at distinct timepoints, 0 h, 1 h 
and 24 h for R9-GFP-H6 and T22-GFP-H6 samples. As expected, no pNPs were 
visualized in VP1-GFP samples. Self-assembled pNPs were detected immediately after IB 
resuspension in PBS, time 0 h, and at all the tested times. Thus, we confirmed that a 
significant part of the signal obtained in the western blot analysis was given by a 
nanostructured fraction of the protein. In addition, size distribution was determined for both 
R9-GFP-H6 and T22-GFP-H6 released pNPs. As it can be observed in Figure 2 bi, T22-
GFP-H6 exhibited particles with a peak between 10 and 20 nm in diameter, slightly smaller 
than the ones obtained for R9-GFP-H6. In this last case the peak was shifted between the 
20 and 30 nm. In both samples, bigger particles (untill 130 nm), could be observed but 
they represented a negligible number of the released material. Interestingly, these results 
are in accordance with size distribution obtained for T22-GFP-H6 pNPs when produced 
from the protein soluble form [30].  
 
Figure 2. In vitro protein release from T22-GFP-H6, R9-GFP-H6 and VP1-GFP IBs a) Protein 
amount determination by western blot of insoluble fraction (I) and soluble fraction (S) at different 
incubation time points ai) Relative protein quantification from the soluble and insoluble fraction of 
T22-GFP-H6 and R9-GFP-H6 samples at distinct incubation time points. b) FESEM morphometric 
analysis of pNP present in the soluble fraction and released from IBs at 0 h, 1 h and 24 h of IB 
suspension incubation. bi) Size distribution of pNPs for T22-GFP-H6 and R9-GFP-H6.   
To validate if R9-GFP-H6 and T22-GFP-H6 pNPs released from IBs maintained their 
bioactive properties, such as CXCR4 receptor avidity, in vitro internalization studies of 
released protein particles were carried out (Figure 3). pNPs from R9-GFP-H6 and T22-
GFP-H6 showed significant internalization after 1 h of incubation in CXCR4+ HeLa cells. In 
addition, when the CXCR4 inhibitor AMD 3100 was added, pNP uptake was completely 
blocked indicating that R9-GFP-H6 and T22-GFP-H6 get into the cells by CXCR4 
receptor-specific mediated endocytosis. As expected, no uptake was observed for VP1-
GFP samples. This data was confirmed by confocal microscopy (Figure 3c). 
 
Figure 3. Internalization of pNPs released and isolated from IB suspensions in CXCR4+ cells. 
a) Internalization  of soluble pNPs (isolated from IBs) monitored by flow cytometry 1h after exposure 
to HeLa cells .b) Inhibition of T22-GFP-H6 and R9-GFP-H6 pNPs (isolated from IBs) internalization 
by CXCR4 receptor specific antagonist AMD3100. c) Confocal images of HeLa cells exposed to 
isolated pNPs (released from IBs) for 1h. In blue: cell nuclei, in red: cell membrane, in green: 
internalized pNPs. *: p<0.05 
Finally, as a proof of concept for the developed biomaterial acting as reservoirs of pNPs, in 
vivo assays were also performed. Colorectal cancer xenograft models bearing 
subcutaneous tumors in the mouse anterior flank were subcutaneously injected in the 
mouse posterior flank with 1 mg of T22-GFP-H6 IBs per mouse, far away from the tumor 
location. SC Injection of 1 mg of VP1-GFP IBs were used as non-pNP releasing negative 
control. Screening of fluorescence by IVIS revealed a relatively low release of the material 
from the injection point for VP1-GFP IBs. The release of T22-GFP-H6 was significantly 
higher, with a marked drop in fluorescence during the first 2 days that was then stabilized 
maintaining the levels until day 10 after injection (Figure 4a). 
Looking at the fluorescence emitted by the protein in blood it can be drawn that detectable 
amounts of T22-GFP-H6 and VP1-GFP were released from the injection site, reached the 
blood vessels in the hypodermis and entered the blood stream (Figure 4b). The amount of 
T22-GFP-H6 material able to reach the blood stream was significantly higher than that of 
the VP1-GFP protein, probably due to their capability to release a higher extent of protein 
and to self-assemble in pNPs. The concentration of T22-GFP-H6 in blood showed a 
progressive increase until day 5 and was detectable until 10 days after IB subcutaneous 
injection. The concentration of VP1-GFP (pNP negative control) in blood did not 
experiment important changes along  time. These results are in accordance with the 
multiple immunolabeling at the injection site. As it can be observed in Figure 4c, T22-
GFP-H6 showed important level of disaggregation of the subcutaneously injected IBs 
leading to a high degree of dispersion of the forming material and penetration into the 
surrounding tissue. Noteworthy, GFP labeling was also detected inside blood vessels, 
delimited by the immunolabeling of the endothelial marker PECAM. This observation 
provided direct evidence of the high capability for the released T22-GFP-H6 protein to 
enter the vessels and subsequently the bloodstream enabling its further distribution to 
specific tissue in a distal point of the body. On the contrary, VP1-GFP showed a compact 
distribution of the deposited IBs within the subcutaneous tissue with little spreading, 
making it more difficult to reach and enter the blood vessels. 
 
Figure 4. Assessment of T22-GFP-H6 and its respective control VP1-GFP protein release in 
mice upon subcutaneous administration of 1 mg dose/mouse of each IB type. a) On the left 
panel, ex- vivo FLI representative images at the injection site after 0 d, 1 d, 2 d, 5 d and 10 d. On 
the right graphic representation of the FLI obtained at the injection site for all the animals. b) Protein 
detected in blood at 0 d, 1 d, 2 d, 5 d and 10 d upon IB subcutaneous injection. c) Multiple 
immunofluorescence image at the injection site after 5 d post IBs administration displaying in green 
GFP protein, in blue cell nuclei and in red the endothelial marker PECAM-1.*: p-value <0.05 
between groups; ɸ p-value <0.05 between the rest of T22-GFP-H6 treated groups.   
In order to track the protein released from these IBs, the emitted fluorescence was 
measured to assess their uptake in tumor tissue, as well as in brain, lung, heart, liver, 
kidney and bone marrow to assess unspecific accumulation in non-target organs. Protein 
was detected in tumors as it can be observed in Figure 5. Noteworthy, fluorescent signal 
increased along time showing stable accumulation of pNPs in the tumor for T22-GFP-H6 
sample. T22-GFP-H6 exhibited maximum accumulation at day 5 and slightly decreased till 
day 10 upon IB injection. VP1-GFP injected animals also exhibited fluorescence at all 
tested timepoints in tumors, denoting protein release from the material deposited at the 
injection site, but no accumulation during this period was observed. In fact, the retained 
amount of protein in the tumor and the subsequent fluorescence levels decreased along 
time and were markedly lower than the ones obtained for T22-GFP-H6 samples at long 
times, 5 and 10 days upon IB administration. Moreover, in the case of T22 empowered 
pNPs multiple immunofluorescence images displayed GFP signal clustered in the 
perinuclear region of tumor cells indicating the capability of released pNPs to be actively 
internalized by CXCR4+ malignant cells.  
 
Figure 5. Tumor ex- vivo accumulation of T22-GFP-H6 and its respective control VP1-GFP 
proteins in mice upon subcutaneous administration of 1mg dose/mouse of each IB type. a) 
On the left panel, ex- vivo FLI representative images of protein accumulation in tumor after 1 d, 2 d, 
5 d and 10 d IB injection. On the right graphic representation of the FLI obtained for all the animals.  
b) Multiple immunofluorescence after 5 d post IBs administration image in tumor displaying in green 
GFP protein, in blue cell nuclei and in red the endothelial marker PECAM-1. * p-value <0.05 
between groups. c) Plots describing the insoluble IBs remaining in the hypodermis, the amount of 
released soluble pNPs and the amount of soluble pNPs that reach the tumor and the kidney along 
time. The areas under the curve (AUCs) are used to estimate the percent of injected IBs and of 
released proteins that reach the tumor and renal tissues. Please, see Suppl. Table 1 for quantitative 
data. 
Ex-vivo analysis of non-targeted organs revealed fluorescent signal at short times in 
kidney for T22-GFP-H6. This signal faded after 1 day indicating that part of the material is 
either cleared through these organs, in the case of protein in its monomeric form, or 
retained in the renal glomerule to be further recirculated to the bloodstream, in the case of 
nanostructured protein. On the contrary, VP1-GFP showed a much more erratic 
distribution in accordance with their non-targeted nature and incapability to generate 
pNPs. Several organs, particularly the liver, contained detectable amounts of the VP1-GFP 
protein 1 day post-injection.  
Next, we estimated the percent of injected dose that reached the tumor or the kidney (the 
normal organ with highest accumulation) out of the total soluble protein released from the 
IBs in the hypodermis, after the subcutaneous administration of 1 mg IBs dose. (Figure 
5c, Suppl.Table 1). After administration of T22-GFP-H6 IBs, the protein was continuously 
released as soluble pNPs (83.6 %). Only a small percent of it remained in the hypodermis 
by day 10. Moreover, the released soluble protein accumulated mainly in tumor tissue 
(33.7%), whereas a minor fraction (2.7%) was uptaken by the kidney and negligible 
accumulation was detected in other normal organs. That implied 12.3 times more 
accumulation of T22-GFP-H6 pNPs in tumor than in kidney. The rest of the released 
soluble protein was likely degraded in blood or in tumor tissue after cell internalization. 
Noteworthy, excluding the pNP slow release, provided by the SC IBs administration, the 
distribution and degradation in the body of the released pNPs followed a similar pattern to 
the one we previously reported after direct intravenous administration of soluble T22-GFP-
H6 pNPs [18] .  
In contrast to T22-GFP-H6 IBs, a much lower amount of VP1-GFP IBs (14.2%) was 
released as soluble protein. Out of that, 5.7% of released protein was uptaken by the 
tumor whereas 3.3% accumulated in the kidney (suppl. Table 1, Figure 5c). This data 
indicates that T22 peptide is effectively conferring selectivity to the T22-GFP-H6 pNPs 
released from IBs to CXCR4+ tumors while our non targeted control VP1-GFP showed, as 
expected, a poor selectivity in our model.   
 
Figure 6. Organ biodistribution of T22-GFP-H6 and its respective control VP1-GFP in mice at 
5 h and 1 d, 2 d, 5 d  and 10 d upon subcutaneous administration of 1 mg dose/mouse of 
each IB type. Representative ex vivo images of targeted and untargeted IB uptake in mouse brain, 
lung, heart, liver, kidney and bone marrow tissue after subcutaneous injection measured by GFP-
emitted fluorescence.  
  
Discussion: 
Classical perception of bacterial IBs as non-functional protein aggregates has been 
overcome for a while. Many studies have shown the potential of these protein particles in 
several fields, reviewed elsewhere [31,32]. In biomedical research the protein nature of the 
material confers enormous structural and functional possibilities empowering the 
appearance of more complex and finest biomaterials. Other examples of the potential of 
protein based biomaterials are polymeric materials using as building blocks silk, elastin, 
collagen and resilin recombinant proteins or protein fragments. This kind of biomaterials 
has been shown able to render nanoparticles but also bigger, insoluble structures such 
hydrogels [33]. Nevertheless, the combination of both supramolecular conformations using 
the same recombinant construct has never been attempted. In our case, production of 
T22-GFP-H6 and R9-GFP-H6 modular proteins engineered to oligomerize into pNPs 
[17,34], in a first level of structural complexity at the nanoscale, can be combined with their 
production and isolation in bigger entities as insoluble IBs, what confers a second grade of 
structural complexity. These multifaceted protein delivery platforms exhibit appealing 
features such as biocompatibility, biodegradability, cell targeting capacity, long lasting 
effect and plasticity to modulate their physicochemical properties. Hence, we expect when 
formed by proteins with a therapeutic activity they will be able of increasing treatment 
efficiency and reducing non-desired side effects. This idea is reinforced by the recent 
results obtained when producing self assembled pNPs formed by toxins or pro-apoptotic 
peptides replacing the GFP backbone and using the same architectonic tags than in the 
present work. In this scenario, toxin and pro-apoptotic based pNPs revealed a strong 
therapeutic potential after intravenous injection in colorectal cancer mouse model [35,36]. 
Our data prove the feasibility of producing pNPs, formed by self-assembling of modular 
proteins immobilized as IBs. The resulting pNPs were successfully isolated from those 
insoluble supramolecular structures, avoiding complex purification and refolding processes 
and therefore reducing substantially downstream costs [31]. Interestingly, although pNPs 
self-assembly has been described in non-physiological conditions [34] no evidence of pNP 
formation in the bacterial cytoplasm has been provided so far. Nevertheless, the presence 
of pNPs in straightforward isolated IBs, together with the observation of distinct surface 
roughness, resembling a particulate coating and even rounded structures in the nano 
scale attached to the IB surface (see suppl. Figure 1) allows to speculate that pNPs self-
assembly could occur, at least partially, in the bacterial cytoplasm during protein over 
expression. In this situation part of the recombinant protein would skip the cell protein 
quality control machinery to be deposited in the insoluble amyloid-like aggregates. The co-
existence of soluble and insoluble protein species inside the bacteria cytoplasm would 
enable the possibility for soluble pNPs to be trapped in the insoluble amyloid network as 
previously described for non-nanostructured soluble protein [37,38].  
As it happens with the conformational quality of the protein embedded in the IBs [39,23] 
pNPs release from these protein deposits could also be tuned by the genetic modification 
of the forming protein. Distinct release patterns observed for proteins with the same GFP 
scaffold but different ligands, T22 and R9, exemplify how this material can be engineered 
from their genetic sequence to modulate their associated mechanical properties such as 
pNPs release profile. In our system, T22-GFP-H6 exhibited a sustained release along the 
tested times while R9-GFP-H6 showed a burst of pNPs after short incubation times.  
Besides, IBs per se are a highly malleable biomaterial which physico-chemical properties  
can be modulated by adjusting other process variables such as harvesting time or protein 
overexpression temperature [40]. The proper choice of the bacterial genetic background 
used as cell factory has shown significant impact in biological activity of the resulting 
protein deposit and its morphometric parameters [41]. Interestingly, the genetic profile of 
microbial cell factories also influences pNPs features [29]. It is important to note that 
protein conformational quality of the resulting pNPs was not compromised by their 
production as IBs. Internalization assays in CXCR4+ cells and further uptake competition of 
isolated pNPs (released from IBs) with AMD3100 indicated that receptor specificity, 
directly dependent on the proper T22 ligand folding [29], remained intact. Targeting is 
crucial in DDS design since it allows reducing drug effective concentration, focuses the 
therapeutic action at the desired organ or cell type and restrain undesired off target effects. 
In this regard, our model system proved to be a simple “all in one” approach from the 
biofabrication point of view rendering complex sub-micron particles that act as a novel 
platform for the sustained release of fully active targeted pNPs. 
Moving to the in vivo scenario, our injected IBs were able to release protein. This protein 
entered the blood stream, travelled through the mouse body and targeted distal CXCR4+ 
tumors where significantly accumulated, being detectable after 10 days upon 
subcutaneous injection (Figure 7).  
 
Figure 7. Scheme of the pathway followed by targeted T22-GFP-H6 IBs upon subcutaneous 
implantation.  Subcutaneously injected T22-GFP-H6 IBs release pNPs or monomeric T22-GFP-H6 
able to cross into the blood stream and accumulate in distant CXCR4+ tumors. Nanostructured 
protein would be easily internalized by CXCR4+ cells and avoid renal clearance.  
The material released from these insoluble reservoirs was able to penetrate the 
surrounding tissue at the injection site and implied a sustained concentration of the 
potentially therapeutic agent in blood. This provided a constant income with maintained 
levels and long lasting effect instead of the usual oscillatory levels with punctual high 
concentration peaks occurring when NPs or other soluble drug are administrated 
intravenously [42]. In this regard, T22-GFP-H6 pNPs have been previously described as a 
promising DDS for colorectal cancer treatment [18]. In addition, it has been shown that 
T22-GFP-H6 pNPs successfully accumulate in CXCR4+ tumors after 24 h upon 
intravenous administration but their presence was almost non-existent at 48 h [18,8]. 
These results contrast with our data showing a significantly longer half-life of pNPs within 
the body when implanted subcutaneously packed as IBs. In this last case, fluorescence in 
blood and accumulation in tumors were detected after 10 days post subcutaneous 
injection. Nevertheless, biodistribution and intracellular T22 driven targeting of pNPs 
released from IBs and previous studies using pNPs self-assembled from T22-GFP-H6 
soluble protein showed very similar patterns. In both cases notable accumulation in the 
targeted tumor and little off target detection of pNP have been observed indicating that 
pNPs released from IBs are fully functional in the in vivo context.  
The pharmacokinetic/ pharmacodynamic (PK/PD) behavior of each novel therapeutic 
protein SC injected as IBs may depend on the IBs release kinetics of soluble pNPs from 
the hypodermis to enter the bloodstream and also on the capacity of the released and 
targeted pNPs to penetrate tumor tissue and internalize in target cancer cells (in our case 
CXCR4+ cancer cells), through receptor-dependent endocytosis. This will require specific 
studies devoted to demonstrate the reproducibility of its kinetic behavior and the 
optimization in a trial-and-error approach to obtain the appropriate mechanical properties 
of the DDS that fulfill the prospected therapeutic application.  
In contrast, although the fluorescent signal in tumors was also detectable for VP1-GFP 
samples there was no accumulation along the time. This suggests punctual increased 
concentration of VP1-GFP at tumor site probably by EPR effect but a lack of internalization 
of the protein into tumor cells. These results are supported by the immunofluorescence 
images showing faint and diffuse signal for the VP1-GFP samples in tumor after 5 d upon 
IBs injection.  
Although pNPs release have been demonstrated in vitro, protein release in a monomeric 
form cannot be completely discarded. However, our results indicate that an important 
amount of the released material is in form of already assembled pNPs or self-assembled in 
the microenvironment at the implantation site. An elegant study performed by Cespedes 
and co-workers has recently described how to determine pNP architectural stability in vivo 
by the analysis of renal clearance [30]. This study showed how monomeric protein, smaller 
than 7 nm, is rapidly cleared through renal filtration while bigger entities such pNPs avoid 
renal filtration enhancing their blood circulation time and accumulation in the target tissues. 
Additional studies have shown also a strong influence of nanoparticle surface charge in 
renal filtration showing how negatively charged particles are better retained than the 
positively charged ones [43]. In this regard, T22-GFP-H6, when self-assembled in pNPs 
has been previously described as slightly negatively charged pNPs, z potential = -17.2 mV, 
(unpublished data). These facts indicate that fluorescent signal observed in tumors for 
T22-GFP-H6 samples comes from nanostructured particles. In accordance, we observed 
at short times upon T22-GFP-H6 subcutaneous injection, some fluorescence in kidney that 
faded away at longer time points, while a diffuse but more stable signal along time was 
detected for VP1-GFP IBs. Nevertheless, T22-GFP-H6 signal observed in kidney for these 
samples appeared focused and exhibited notable levels of fluorescence. Monomeric 
protein is likely to be fast cleared away unable to render such fluorescence intensity. Thus, 
this concentrated fluorescence observed in kidney could be partially due to temporary 
retention of the pNP in the renal glomerule that eventually would enter the bloodstream 
again. In the case of VP1-GFP the lower and slower material release from the IB would be, 
as expected, mainly in form of monomeric protein since no significant accumulation is 
detected in either targeted tumors or off target tissues. In summary T22-GFP-H6 IBs can 
release protein in both pNPs form and in a lesser extent, monomeric form but the self-
assembled fraction represents the predominant conformation of the released material at all 
the tested points. 
Other biomaterials have been developed to provide a sustained release of the effector 
molecule from a biodegradable matrix or to be functionalized by the addition of biological 
components such as peptides [44,45]. However, their fabrication implies the production 
and conjugation of several components while in our approach we obtain a complex 
biomaterial in a single step by simple protein overexpression and deposition as insoluble 
protein clusters. IB suprastructure would act as a deck from where pNPs are released, 
resembling star fighters being launched from their base. These pNPs in turn can reach the 
bloodstream to be further distributed through the body providing a long lasting effect and 
an increased safety margin. In our case pNPs were targeted to CXCR4+ colorectal cancer 
tumors by the addition of T22 ligand in the modular protein. Noteworthy, this new approach 
in which pNPs are released from bigger entities such bacterial IBs could be adapted to an 
uncountable number of distinct diseases treatments by replacing both, the ligand that 
provides target specificity as well as the GFP reporter protein by other polypeptides with 
therapeutic activity as well as by adjusting production variables in order to tune 
physicochemical properties of the IBs. However, this optimization process is protein 
construct dependent and will need to be addressed in a trial-and-error based process to 
obtain the drug delivery system with the desired properties.  Still, the use of biomaterials 
with bacterial origin can raise some concerns about the safety of the final product for 
implantable devices. In this regard, the development of new bacterial strains and protein 
production of IBs in GRAS organisms are addressing this issue [46,47] with promising 
results. 
Conclusion: 
In the present study we have generated novel smart biomaterials gathering most of the 
desirable features for implantable DDS, with cost effectiveness and simplicity in the 
biofabrication process. In this regard, single step fabricated IBs when injected 
subcutaneously rendered a long lasting release of  targeted pNPs, able to enter to the 
blood stream and specifically target the tumor for as long as 10 days. We have described 
for the first time an approach for the fabrication of protein DDS based on protein deposition 
as IBs and their sustained release in form of fully functional targeted pNPs. This 
technology provides and stable source of targeted protein nanoparticles during long 
periods within the body with the action at distal points from the implantation site and pave 
the way for the appearance of new more efficient and less invasive treatments for a broad 
number of pathologies. 
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